Companies: 48,874 Total Market Cap: 132456628851223.12

Innovent Biologics

HKG-1801
Healthcare Biotechnology
Rank #1701
Market Cap 11.18 B
Volume 16.27 M
Price 7.06
Change (%) 4.24%
Country or region Hong Kong Hong Kong

Innovent Biologics's latest marketcap:

11.18 B

As of 05/20/2025, Innovent Biologics's market capitalization has reached $11.18 B. According to our data, Innovent Biologics is the 1701th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 11.18 B
Revenue (ttm) 1.28 B
Net Income (ttm) -12,863,889.11
Shares Out 1.65 B
EPS (ttm) -0.01
Forward PE 210.15
Ex-Dividend Date n/a
Earnings Date 08/22/2025
Market Cap Chart
Data Updated: 05/20/2025

Innovent Biologics's yearly market capitalization.

Innovent Biologics has seen its market value drop from HK$115.10 B to HK$87.51 B since 2020, representing a total decrease of 23.97% and an annual compound decline rate (CAGR) of 6.06%.
Date Market Cap Change (%)
05/20/2025 HK$87.51 B 40.31%
12/31/2024 HK$59.96 B -13.32%
12/29/2023 HK$69.17 B 34.57%
12/30/2022 HK$51.40 B -27.14%
12/31/2021 HK$70.55 B -38.71%
12/31/2020 HK$115.10 B

Company Profile

About Innovent Biologics, Inc.

Innovent Biologics, Inc. is a biopharmaceutical company specializing in the development and commercialization of monoclonal antibodies and other drug assets. The company focuses on therapeutic areas including oncology, ophthalmology, autoimmune disorders, and cardiovascular and metabolic diseases, primarily serving the People’s Republic of China.

Key Products

  • Tyvyt: A human anti-PD-1 monoclonal antibody.
  • BYVASDA: A fully-human anti-VEGF monoclonal antibody.
  • HALPRYZA: A recombinant chimeric murine/human anti-CD20 monoclonal antibody.
  • SULINNO: A fully-human anti-TNF-α monoclonal antibody.
  • Pemazyre: A selective FGFR inhibitor.
  • Olverembatinib: A novel BCR-ABL TK.
  • Cyramza: A VEGF receptor 2 antagonist.
  • Retsevmo: A selective and potent RET kinase inhibitor.

Pipeline Developments

  • IBI-326: A fully-human BCMA CAR T-cell therapy.
  • IBI-376: An oral inhibitor of PI3Kδ.
  • IBI-351: A KRASG12C inhibitor.
  • IBI-344: A repressor of silencing 1/TRK tyrosine kinase inhibitor.
  • IBI-126: An ADC targeting CEACAM5.
  • IBI-306: A novel anti-PCSK9 monoclonal antibody.
  • IBI-362: A GLP-1R/GCGR dual agonist.
  • IBI-112: A long-acting anti-IL-23.

Additional Research & Services

Innovent Biologics also engages in pharmaceutical distribution and provides consultation, research, and development services. The company was founded in 2011 and is headquartered in Suzhou, China.

Frequently Asked Questions

As of 05/20/2025, Innovent Biologics (including the parent company, if applicable) has an estimated market capitalization of $11.18 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Innovent Biologics global market capitalization ranking is approximately 1701 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Hong Kong
Founded 2011
IPO Date n/a
Employees 5,659
CEO De-Chao Yu
Sector Healthcare
Industry Biotechnology
Address 168 Dongping Street
Suzhou, 215123
China
Website https://www.innoventbio.com
People Also Watch
VRTX
440.66 6.66%
CSL Limited
157.08 6.66%
REGN
596.54 6.66%
KRX-207940
732.96 6.66%